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Summary 
Background:  Newer antiepileptic drugs (AED) are increasingly prescribed, and seem to have 
a comparable efficacy as the classical AED, but are better tolerated. Very scarce data exist 
regarding their prognostic impact in patients with status epilepticus (SE). We therefore 
analyzed the evolution of prescription of newer AED between 2006-2010 in our prospective 
SE database, and assessed their impact on SE prognosis. 
Methods:  We found 327 SE episodes occurring in 271 adults. The use of older versus newer 
AED (levetiracetam, pregabalin, topiramate, lacosamide) and its relationship to outcome 
(return to clinical baseline conditions, new handicap, or death) were analyzed. Logistic 
regression models were applied to adjust for known SE outcome predictors. 
Results:  We observed an increasing prescription of newer AED over time (30% of patients 
received them at the study beginning, vs. 42% towards the end). In univariate analyses, 
patients treated with newer AED had worse outcome than those treated with classical AED 
only (19% vs 9% for mortality; 33% vs 64% for return to baseline, p<0.001). After 
adjustment for etiology and SE severity, use of newer AED was independently related to a 
reduced likelihood of return to baseline (p<0.001), but not to increased mortality. 
Conclusion:  This retrospective study shows an increase of the use of newer AED for SE 
treatment, but does not suggest an improved prognosis following their prescription. Also in 
view of their higher price, well-designed, prospective assessments analyzing their impact on 
efficacy and tolerability should be conducted before a widespread use in SE.  
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Status epilepticus (SE) represents a common neurological emergency that is associated with 
significant mortality and morbidity (Lowenstein, 1999), and thus requires a prompt 
management to avoid neurological sequelae or death (Lowenstein & Alldredge, 1998; 
Shorvon, 2001). 
Current SE treatment protocols advocate a three-step approach, with benzodiazepines as 
initial therapy followed by the use of antiepileptic drugs (AED) administrated intravenously 
(Meierkord et al., 2010). When SE is refractory to the two first treatment lines, a coma 
induction with an anaesthetic agent may be necessary (Lowenstein, 1998; Meierkord et al., 
2010). Newer AED have been increasingly marketed since about two decades; globaly, 
efficacy seems unchanged as compared to traditional AED, but they are generally better 
tolerated (Kwan & Brodie, 2003). These compounds are increasingly prescribed, although 
indications other than epilepsy seem to contribute to this trend (Alacqua et al., 2009). Newer 
AED have been used in the treatment of SE in the last years, both in oral (Towne et al., 2003; 
Rossetti & Bromfield, 2006; Novy & Rossetti, 2010; Stojanova & Rossetti, 2011), and 
intravenous forms (Berning et al., 2009; Rüegg et al., 2008; Knake et al., 2008;  Kellinghaus 
et al., 2011). It remains however unclear if the use of newer AED has lead to an improved 
prognosis in patients suffering from SE, and whether they are increasingly used in this setting. 
The aim of this study was to describe the evolution of prescription of newer AED in SE 
treatment over the years 2006–2010 in our hospital, and to investigate their impact on SE 
prognosis.  
 
Methods  
Database, patients, SE definition 
Our prospective SE database (Novy & Rossetti, 2010) that identifies adults with SE episodes 
admitted to our center (a University hospital) was retrospectively analysed for this study; the 
period considered spans between April 1, 2006 and September 30, 2010. Patients were 
identified by 2 epileptologists and the neurologic consulting team; EEG were systematically 
performed for every patient with a suspicion of SE. Status epilepticus was considered as an 
epileptic seizure lasting more than 30 minutes, or several epileptic seizures without return to 
baseline between seizures. Patients under 16 years and episodes of post-anoxic SE were not 
included due to markedly different prognostic implications. 
Definition of variables 
Age, gender, history of previous seizures, seizure types (partial vs. generalized), level of 
consciousness, SE duration, time to treatment, treatment type and etiology of SE were 
prospectively identified. Older age, extent of consciousness impairment, and acute 
symptomatic etiology have been consistently shown to be independently related to poor 
outcome following SE (Logroscino et al., 1997; Towne et al., 1994; Chin et al., 2004; 
Claassen and al., 2002; Schneker & Fountain, 2003; Rossetti et al., 2006); the SE severity 
score (STESS), a validated clinical prognostic tool considering age, seizure type, 
consciousness impairment, and history of previous seizures (as etiology surrogate), was 
prospectively calculated for each patient on admission and dichotomized in the database as <3 
(favourable) or ≥3 (unfavourable) (Rossetti et al., 2008). Etiology was considered as 
“potentially fatal”, in analogy to previous works,  if leading to death without an appropriate 
treatment independently of SE (Rossetti et al., 2006; Novy et al., 2010). These etiologies 
include for example: massive ischemic and hemorrhagic stroke, primary or secondary cerebral 
tumor, central nervous system (CNS) infection, severe autoimmune disease, AIDS with CNS 
complication, and metabolic disturbance sufficient to cause coma, eclampsia, and sepsis. 
Use of AED for SE treatment was prospectively recorded in the database; for the purpose of 
this analysis, topiramate, levetiracetam, pregabalin and lacosamide were considered as newer 
AEDs ; in fact, other newer AED (such as lamotrigine, gabapentine, felbamate, vigabatrine, 
tiagabine, oxcarbazepine, or retigabine) were practically never used in a SE setting in our 
hospital. Classical AED mainly used in SE in our database are phenytoin, valproate, 
barbiturates, and benzodiazapines. SE episodes were dichotomized into those with at least one 
newer AED (irrespective of the medication) or not. Outcome at hospital discharge was 
prospectively categorized as return to baseline clinical conditions, disabled (i.e., presence of a 
new handicap), or death. 
Statistical analysis 
The prevalence of use of newer AED, and clinical prognosis, were first described according to 
two periods, defined by the availability of intravenous formulations of levetiracetam and 
lacosamide in our hospital (April 1, 2006 to September 30, 2007;  October 1, 2007 to 
September 30, 2010). Subsequently, we analyzed outcome distribution according to the use of 
newer AED, and robust SE outcome predictors (etiology, STESS). Frequency tables were 
assessed using χ2 tests. Finally, stepwise multivariable logistic regressions were used to 
evaluate the impact of use of newer AED on prognosis, adjusting for other predictors; models 
were evaluated with the Hosmer-Lemeshow test. All calculations were performed with the 
version 9 of the Stata software (College Sattion, TX, USA); significance was considered at 
p<0.05.   
 
Results 
We identified 327 SE episodes occuring in 271 patients during the 54-months study period. 
Mean age was 60 years (SD ± 18.3). There were 176 women (53.8%); 40 patients (14.8%) 
presented more than one SE episode. Over the 5-year period, 128 SE episodes (39.2%) were 
treated with at least one of the newer AED, 70 of them were women (54.7%), and mean age in 
this group was 59 years (SD ±16.7; range 16-92). We observed a trend favouring the use of 
newer AED during the second period of time (102 episodes, 42.2%) over the first one (26 
episodes, 30.6%) (p=0.060) (Table 1). 
Prognosis according to the two chronological periods showed non-significant differences, 
with a slightly higher mortality in the earlier period (p=0.303) (Table 2). However, in 
univariable analyses, patients treated with newer AED had a worse outcome than patients 
receiving only classical AED during the entire study period (Table 3).  
In the studied cohort, patients with a potentialy fatal etiology were more often treated with 
newer AED. There was also a trend to treat patients with a high STESS (≥3-6) more often 
with newer AED (Table 4). After adjustment for potentially fatal etiology and SE severity 
score (that included age, seizure semiology, extent of consciousness impairment, and history 
of previous seizures), use of newer AED was significantly related to a higher risk of lack of 
return to baseline clinical conditions at discharge, but not to inscreased mortality. Both 
models showed an acceptable goodness of fit, and confirmed the robustness of STESS and 
etiology as independent outcome predictors (Table 5). 
Discussion 
This study focusing on the prescription of newer AED in patients with SE shows that their use 
tended to increase over the past 5 years. Moreover, treatment of SE with newer AED was 
associated with increased disability at hospital discharge, but not higher mortality.  
A similar trend of increased prescription of newer AED has been already shown in recent 
studies (Alacqua et al., 2009; Savica et al., 2007); although that seemed to at least partly 
reflected extra-epileptic indications (e.g., neuropathic pain), other studies demonstrate that 
newer AED are increasingly used in patients with epilepsy (Pugh et al., 2008); however, the 
speed of this rise appears relatively modest (Hsia et al., 2010). To the best of our knowledge, 
a similar analysis has not been yet performed in patients with SE, and confirms the global 
trend.  
In univariable analyses, patients who only received classical AED had a more favorable 
prognosis than those who also received newer AED (p<0.001). This differs from previous 
assessments on patients with epilepsy, which globally showed similar efficacy with fewer side 
effects for the newer AED (Beydoun, 1997; Kwan & Brodie, 2003; Vasquez, 2004; Marson et 
al., 2007), and may reflect some confounding in our cohort. In fact, consideration of known 
SE outcome predictors discloses that patients with a potentialy fatal etiology (Rossetti et al., 
2006; Tsai et al., 2009) had received newer AED more often for the treatment of their SE 
episode (p=0.001); furthermore, subjects with a high STESS (≥3) (Rossetti et al., 2008) also 
tended to show a higher chance to be treated with newer AED (p=0.057). These two variables 
thus may explain at least in part the results: patients with SE forms felt to be more aggressive 
had a greater likelihood to receive further compounds of the therapeutic arsenal, including 
newer AED; this is highlighted by the multivariable analysis: after correction for etiology and 
SE severity, only disability, but not mortality, resulted independently related to the use of 
newer AED. A recent study analysing the same database showed a higher rate of SE treatment 
failure with levetiracetam than with valproate but no impact on the outcome at hospital 
discharge (Alvarez et al., 2011). A possible explanation for these results could be that dosages 
of levetiracetam used in our hospital, between 1000-3000 mg daily, were somewhat lower 
than those recently recommended in the literature (3,000-3,500 mg daily) (Berning et al., 
2009; Trinka & Dobesberger, 2009; Shorvon, 2011; Swisher et al., 2011).  
 
While a greater risk of disability after use of newer AED could theoretically reflect some 
reduced efficacy of these compounds, an information bias may also exist regarding the 
outcome. Indeed, the “return to baseline” clinical conditions may depend on the moment it 
was assessed, as disability may evolve over time, as opposed to mortality that represents a 
more “robust” outcome. In our database, outcome was scored at hospital discharge, a variable 
time frame. In fact, mortality was not different among users of newer and classical AED only, 
and the different likelihood of return to baseline may simply reflect the need for a longer 
convalescence after a severe SE episode, even after consideration of two solid SE predictors. 
Our study has some other potential limitations. A selection bias may exist because it considers 
only patients from a university hospital; however, most SE patients are treated in institutions 
with availability of ICU and neurologists. Due to its retrospective design, the analysis does 
not allow us to know whether patients were already receiving the assessed treatements before 
admission, or if these were initiated de novo at hospital during the seizure. Finally, we had no 
information about treatment side-effects. 
In conclusion, despite some increase in the prescription of newer AED for SE treatment over 
the past few years, this study does not support an improved prognosis following their 
prescription, if considered as a group, and corroborates the aforementioned finding on the lack 
of superiority of levetiracetam as compared to valproate or phenytoin (Alvarez et al, 2011). 
Since newer AED are more expensive than classical ones, the marketing efforts aimed at their 
increased use in SE should rely on well-designed, prospective assessments showing their 
superiority (at least regarding side effects). Such studies would be of great importance in this 
clinical setting (Shorvon & Ferlisi, 2011; Rossetti & Lowenstein, 2011).  
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Table 1. Treatment of SE episodes stratified according to two periods of time. 
 Classical AED 
only 
Newer AED p-value (test) 
April 2006- September 2007 59 (69.41%) 26 (30.59%) 0.060 (
2
) 
October 2007- September 2010 140 (57.85%) 102 (42.15%) 
 
Table 2. Prognosis according to two periods of time. 
 Return to baseline Disabled Dead p-value 
April 2006- September 2007 42 (49.41%) 28 (32.94%) 15 (17.65%) 0.303 (
2
) 
October 2007- September 2010 127 (52.48%) 88 (36.36%) 27 (11.16%) 
 
Table 3. Prognosis regarding to the medication in the whole study period 
04 2006 – 09 2010 Return to baseline Disabled Dead p-value 
Classical AEDonly 127 (63.81%) 54 (27.14%) 
 
18 (9.04%) 
 
<0.001 (
2
) 
Newer AED 42 (32.81%) 
 
62 (48.43%) 
 
24 (18.75%) 
 
 
 
Table 4. Prevalence of potential fatal etiology and STESS (status epilepticus severity score) 
regarding to the use of medication in the whole study period 
 No pot. fatal etiology Pot. fatal etiology STESS 0-2 STESS 3-6 
Classical AED only 129 (64.82%) 70 (35.18%) 107 (53.77%) 92 (46.23%) 
Newer AED 59 (46.1%) 69 (53.9%) 55 (42.97%) 73 (57.03%) 
p-value 0.001 (
2
) 0.057 (
2
) 
 
Table 5. Multivariable logistic regression models using risk of lack to return to baseline 
clinical conditions at hospital discharge, or mortality, as outcome. Results are given as OR 
(95% CI).  
 Lack of return to baseline Mortality 
Use of newer AED 3.23 (1.88 – 5.52), p<0.001 1.60 (0.80 -3.21), p=0.18 
STESS 3-6 4.08 (2.42 – 6.89), p<0.001 4.11 (1.80- 9.38), p<0.001 
Potentially fatal etiology 5.14 (3.03 – 8.73), p<0.001 4.32 (2.00 – 9.33), p<0.001 
Goodnes of fit (
2
) 0.23 0.60 
AED = antiepileptic drugs; STESS = Status Epilepticus Severity Score 
 
